Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors
about
The molecular basis of HIV entryHIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersHIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal AntibodiesOptimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodiesShort Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein.Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strainsPartial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation.How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.
P2860
Q26863686-4A722EE6-EEC9-4A5F-B694-C61A01816F69Q28647225-CC4E07C0-6B1C-4973-A59C-2B533E89DFE2Q33900395-9E77479C-F4F5-4463-813A-7F8D6B7BDC83Q35743897-4970A405-7DD2-4D70-AD78-96652D768AABQ35974269-EDE0008F-8321-4A49-9F6E-FA5C64158445Q36105672-9B66481E-0430-4F8E-8DD6-29F610440F16Q36294806-952C7798-56A3-439C-9053-0FC4E8227A82Q36358780-44C5B30E-FCA8-4223-8079-72350704864EQ36526657-021FB3A2-6E14-4E6C-BD27-BB659AB4E37BQ38258468-F8FE3CCC-2AFA-4AFB-A11F-C1BC84D6382DQ38618790-A57E9F83-6FC1-4CA9-A93A-E7918BE48A7DQ38684463-BF214437-1BBD-4E5A-A9C6-8E4F38F893B3Q38989507-0AB4B94C-705C-47DD-AF5A-8FEE25FB4762Q39361526-5B402152-5FCB-4BDB-9945-5A6C1F8A532FQ40295939-BF3950C9-85C7-4ADB-8DEE-05E2B63AD955
P2860
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Env-glycoprotein heterogeneity ...... ntibodies and entry inhibitors
@en
Env-glycoprotein heterogeneity ...... tibodies and entry inhibitors.
@nl
type
label
Env-glycoprotein heterogeneity ...... ntibodies and entry inhibitors
@en
Env-glycoprotein heterogeneity ...... tibodies and entry inhibitors.
@nl
prefLabel
Env-glycoprotein heterogeneity ...... ntibodies and entry inhibitors
@en
Env-glycoprotein heterogeneity ...... tibodies and entry inhibitors.
@nl
P2093
P2860
P1433
P1476
Env-glycoprotein heterogeneity ...... ntibodies and entry inhibitors
@en
P2093
John P Moore
Katie Matthews
Per Johan Klasse
Sophie Holuigue
Thomas J Ketas
P2860
P356
10.1016/J.VIROL.2011.09.019
P407
P577
2011-10-22T00:00:00Z